posted on 2024-08-05, 09:29authored byBenjamin
Nji Wandi, Pedro Dinis, Vilja Siitonen, Gunter Schneider, Robert Schnell, Mikko Metsä-Ketelä
Anthracyclines are microbial natural products with important
antiproliferative
bioactivities that are widely used in anticancer chemotherapy. Several
anthracyclines, including nogalamycin and kosinostatin, contain a
1-hydroxyl group, which is installed by an atypical two-component
mono-oxygenase system. Here, we clarify the structural and mechanistic
basis for 1-hydroxylation. We present the crystal structure of the
NADPH-dependent reductase SwaQ2 in complex with doxorubicin, which
indicates that the reaction is initiated by quinone reduction. The
reduced anthracycline ligand may react with molecular oxygen, leading
to the formation of a peroxide intermediate similar to flavin chemistry.
The structures of the polyketide cyclase-like SnoaL2, involved in
nogalamycin biosynthesis, in complex with substrate and product reveal
a novel catalytic tetrad, which is used to stabilize a reduced reaction
intermediate to direct the reaction toward 1-hydroxylation. Furthermore,
we report the characterization of several unknown anthracycline 1-hydroxylases,
which display varied substrate profiles. The structure of polyketide
cyclase-like KstA15 from the kosinostatin pathway enabled structure-based
protein engineering to expand the substrate specificity of the enzyme
to include glycosylated anthracyclines. Our work provides insight
into how reductase-hydroxylase two-component systems circumvent the
need for organic cofactors or metal ions to catalyze monooxygenations
in several anthracycline pathways.